Notably, patients with active RA who receive anti–IL-6 receptor monoclonal antibodies (tocilizumab) have a significant and rapid reduction of the QT interval values, which correlates with the decrease in both CRP and, more strongly, circulating TNFα levels [62,63]. The gene discussed is CRP; the disease is rheumatoid arthritis.